InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a “Company Superior Proposal”

ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Inc. (OTCBB:INSV) today announced that InSite’s Board of Directors has determined that the previously announced unsolicited offer from a global pharmaceutical company (the “Bidder”) to acquire all outstanding shares of InSite Vision common stock at $0.35 per share in an all-cash transaction constitutes a “Company Superior Proposal” as defined in InSite’s previously announced definitive agreement with QLT Inc. dated as of August 26, 2015 (NASDAQ:QLTI) (TSX:QLT).